Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Legend Biotech surpasses Q2 sales targets, eyes market expansion

Legend Biotech's Q2 performance exceeded expectations with strong sales and positive study data.
The company's financial position is robust, with a healthy cash balance and plans for capacity expansion.
While facing challenges such as competitive pressures and operational optimizations, opportunities for growth exist.
Strategic initiatives focus on product quality, market expansion, and regulatory advancements for CARVYKTI.

Legend Biotech reports robust Q3 sales, eyes profitability targets

Legend Biotech's Q3 performance reflects strong sales driven by CARVYKTI, while maintaining a solid financial position with a focus on expansion.
The company faces challenges in achieving profitability targets and providing clarity on future sales projections.
Opportunities lie in pipeline advancements, collaboration partnerships, and innovative market expansion strategies.

Legend Biotech reports robust earnings, eyes expansion and regulatory milestones

Legend Biotech's strong earnings and cash balance provide stability and growth opportunities.
CARVYKTI's efficacy and convenience position it well, with plans for capacity expansion and partnerships.
Challenges include regulatory scrutiny and the need for clarity on future manufacturing scale-up.
Opportunities lie in extending manufacturing capacity, pipeline advancements, and profitability projections by 2026.

Legend Biotech reports robust Q1 performance and accelerates CAR-T expansion

Legend Biotech's Q1 2024 showcased strong performance with significant revenue growth and expansion plans to meet rising demand.
While facing challenges like sequential sales decrease and increased expenses, the company is leveraging strengths in production capacity and market diversification.
Opportunities lie in regulatory engagements for accelerated approvals, efficient market penetration strategies, and financial flexibility for future growth.
Overall, Legend Biotech's strategic focus on CAR-T therapies positions it well for continued success and innovation in the biopharmaceutical industry.

Legend Biotech excels in Q2, eyes FDA approvals and growth

Legend Biotech's Q2 2024 performance reflects strong sales growth, regulatory milestones, and promising clinical data, positioning the company for future success.
With a solid financial position, expanded production capacity, and ongoing research initiatives, Legend Biotech demonstrates resilience and strategic foresight in a competitive market landscape.
While facing challenges such as political risks and profitability targets, the company remains focused on growth opportunities and value creation for stakeholders.

Legend Biotech excels in Q3 with CARVYKTI growth and strategic advancements

Legend Biotech's Q3 performance reflects strong sales growth, regulatory milestones, and progress in clinical trials, underpinned by a robust balance sheet and strategic leadership appointments.
While challenges in outpatient treatment adoption and trial enrollment persist, the company's focus on innovation and operational excellence presents opportunities for future growth and market leadership.
Overall, Legend Biotech's solid financial standing, coupled with its expanding product portfolio and research capabilities, positions the company favorably for continued success and value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Johnson & Johnson

The European Medicines Agency's CHMP recommended conditional approval of Janssen, a unit of Johnson & Johnson (NYSE: JNJ), and its partner Legend Biotech Corporation's (NASDAQ: LEGN) CAR-T therapy to treat multiple myeloma. The drug, Carvykti (.

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended Janssen Pharmaceutica NV's marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed an

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, was named Newcomer of the Year at the tenth annual Foreign Investment Trophy ceremony hosted by Flanders Investment & Trade (FIT). Flanders Investment and Trade is a Flemish government organization that facilitates investment projects in Flanders, a northern region of Belg

Flanders Investment and Trade Names Legend Biotech Newcomer of the Year

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech announces fourth quarter and full-year 2021 results.

Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Heron Therapeutics

Pieris Pharma

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.

Legend Biotech's IPO was among the Top five largest of 2020. Compared to the other four, Legend's share price has performed exceptionally well.

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory multiple myeloma. The approval covers adult patients who have received four or more prior lines of therapy, including a.

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its first product, CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of ther

CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in conjunction with an announcement to be issued by Legend Biotech's majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the year ended December 31, 2021. For the year ended December 31

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL).

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech has achieved milestone payments under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel).

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, will deliver the company presentation on Tuesday, January 11, 2022 at 2:15 p.m. (Eastern Time). A live webcast of the presentation will be available to investors and other interested p

Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech appoints Dr. Ying Huang, CEO and CFO, to its board of directors.

Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

The stock price of Legend Biotech Corporation (NASDAQ: LEGN) increased by over 4% during intraday trading today. This is why it happened.

Legend Biotech Stock (LEGN): Why The Price Increased Today

The clinical-stage biotech company's stock dropped more than $4 a share from its Tuesday close.

Why Legend Biotech Shares Plummeted 17.6% Wednesday

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel (cilta-cel) in the treatment of multiple myeloma, which were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Cilta-cel is an investigational B-cell

Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma

Legend Biotech Corporation's (NASDAQ: LEGN) collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for ciltacabtagene autoleucel (cilta-cel). Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy for relapsed or refractory multiple myeloma who have received at least three prior therapies.

Why Are Legend Biotech Shares Gaining Today?

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for ciltacabtagene autoleucel (cilta-cel) by its collaboration partner, Janssen Pharmaceutical K.K. (Janssen). Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen rec

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that it will host a hybrid event featuring key opinion leaders (KOLs) in multiple myeloma on Monday, December 13 at 8pm ET. The meeting will detail new and updated data from the CARTITUDE Clinical Development Program for ciltacabtagene autoleucel (cilta-cel). Cilta-cel is an investigational B-cel

Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech today reported its 2021 third quarter unaudited financial results.

Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech today announced that 12 studies were accepted for presentation at the 63rd ASH Annual Meeting and Exposition.

Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) target date for cilta-cel to February 28, 2022.

Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel

Biopharmaceutical company Legend BioTech (LEGN) hit a new 54-week high this Tuesday, up 103.4% this year.  LEGN is a multinational biopharmaceutical company primarily engaged in the discovery and development of cell therapies for oncology.

Legend Biotech Hits New 54-Week High

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech will host its first Research & Development Day on Monday, October 18, commencing at 10:00 a.m. (Eastern Time), at Andaz 5th Avenue.

News for Legend Biotech Stock (LEGN)